Cargando…

Targeted therapy of RET fusion-positive non-small cell lung cancer

Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with considerable efficacy. The RET proto-oncogene is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Zixiong, Qiu, Binxu, Li, Lin, Yang, Bo, Li, Guanghu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793070/ https://www.ncbi.nlm.nih.gov/pubmed/36582799 http://dx.doi.org/10.3389/fonc.2022.1033484

Ejemplares similares

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Applying machine learning techniques to predict the risk of lung metastases from rectal cancer: a real-world retrospective study
por: Qiu, Binxu, et al.
Publicado: (2023)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
por: Wu, Guowu, et al.
Publicado: (2022)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
por: Goldman, Jonathan W., et al.
Publicado: (2023)

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report
por: Scattolin, Daniela, et al.
Publicado: (2023)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
por: An, Li, et al.
Publicado: (2022)

A machine learning-based model for predicting distant metastasis in patients with rectal cancer
por: Qiu, Binxu, et al.
Publicado: (2023)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
por: Park, Ha-Young, et al.
Publicado: (2023)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
por: Nannini, Margherita, et al.
Publicado: (2022)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
por: Leite, Caio Abner, et al.
Publicado: (2023)

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
por: Arora, Aakriti, et al.
Publicado: (2023)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China
por: Pu, Xingxiang, et al.
Publicado: (2023)

Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
por: Huang, Yan, et al.
Publicado: (2023)

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)

RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report
por: Wang, Yucong, et al.
Publicado: (2019)

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2021)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2023)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Leukocyte telomere length is associated with increased risk of endometriosis: a bidirectional two-sample Mendelian randomization study
por: Bai, Chenxue, et al.
Publicado: (2023)

Common gastrointestinal diseases and chronic obstructive pulmonary disease risk: a bidirectional Mendelian randomization analysis
por: Shen, Zixiong, et al.
Publicado: (2023)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o7m0nbvnda3afc07sfbdhnih1u